Loading...

Paul Fanta

Title(s)Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Research Interests
    The diagnosis and management of gastrointestinal cancers has dramatically changed in the past several years. By incorporating biotechnology, bioinformatics, molecular biomarker analyses, pharmocogenomic data, in the setting of prospective clinical trials, we may better identify patients who will benefit from chemotherapy, avoid toxicities from treatment, and develop a predictive therapeutic strategy unique to a patient’s disease. Enrollment of patients with cancers of the colon, rectum, anus, stomach, esophagus, GI stromal tumors, hepatocellular carcinoma, pancreas, gall-bladder, and cholangiocarcinoma into our clinical trials is a priority.

    Education & Training
    BS - Biology/Chemistry/Math, University of Arizona - 1983
    MS - Microbiology/Immunology, University of Arizona - 2001
    MD - University of Arizona - 2001
    Resident - Scripps-Green Hospital, La Jolla, CA - 2001-2004
    Fellowship - Hematology-Oncology, Scripps Clinic, La Jolla, CA - 2004-2007

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase I Trial of Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb 08. PMID: 33571625.
      View in: PubMed   Mentions:    Fields:    
    2. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021 Feb 01; 148(3):702-712. Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK. PMID: 32700810.
      View in: PubMed   Mentions: 2     Fields:    
    4. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer. 2020 Jun 15; 146(12):3450-3460. Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. PMID: 31782524.
      View in: PubMed   Mentions: 1     Fields:    
    5. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019 12 04; 12(1):130. Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. PMID: 31801585.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    6. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precis Oncol. 2019; 3. PMID: 33015522.
      View in: PubMed   Mentions:
    7. Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. Cancer Metastasis Rev. 2019 09; 38(3):525-535. Neppala P, Banerjee S, Fanta PT, Yerba M, Porras KA, Burgoyne AM, Sicklick JK. PMID: 31773431.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    8. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. . 2019 10; 18(10):1852-1862. Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R. PMID: 31320401.
      View in: PubMed   Mentions:
    9. Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry. J Surg Oncol. 2019 Sep; 120(4):715-721. Stuart E, Banerjee S, de la Torre J, Wang Y, Scherzer N, Burgoyne AM, Parry L, Fanta PT, Ramamoorthy S, Sicklick JK. PMID: 31297829.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 07 01; 17(7):855-883. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA. PMID: 31319389.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    11. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019 05; 25(5):744-750. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. PMID: 31011206.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    12. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precis Oncol. 2019; 3. Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R. PMID: 31032472.
      View in: PubMed   Mentions:
    13. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253.
      View in: PubMed   Mentions:
    14. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018 12 15; 24(24):6248-6256. Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. PMID: 30348637.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    15. Genomic Landscape of Appendiceal Neoplasms. JCO Precis Oncol. 2018; 2. Ang CS, Shen JP, Hardy-Abeloos CJ, Huang JK, Ross JS, Miller VA, Jacobs MT, Chen IL, Xu D, Ali SM, Baumgartner J, Lowy A, Fanta P, Ideker T, Millis SZ, Harismendy O. PMID: 32913983.
      View in: PubMed   Mentions:
    16. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 06; 16(6):693-702. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. PMID: 29891520.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    17. A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy. J Natl Compr Canc Netw. 2018 03; 16(3):238-242. Charo LM, Burgoyne AM, Fanta PT, Patel H, Chmielecki J, Sicklick JK, McHale MT. PMID: 29523662.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. Cancer. 2018 03 15; 124(6):1288-1296. Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R. PMID: 29211306.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    19. The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. . 2018 01; 17(1):297-305. Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R. PMID: 29133621.
      View in: PubMed   Mentions:
    20. Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. Cancer Res. 2017 11 15; 77(22):6313-6320. Bieg-Bourne CC, Millis SZ, Piccioni DE, Fanta PT, Goldberg ME, Chmielecki J, Parker BA, Kurzrock R. PMID: 28939679.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    21. Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations. JCO Precis Oncol. 2017; 2017. Burgoyne AM, De Siena M, Alkhuziem M, Tang CM, Medina B, Fanta PT, Belinsky MG, von Mehren M, Thorson JA, Madlensky L, Bowler T, D'Angelo F, Stupack DG, Harismendy O, DeMatteo RP, Sicklick JK. PMID: 29938249.
      View in: PubMed   Mentions:
    22. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. PMID: 28807936.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    23. Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis. JAMA Surg. 2017 05 01; 152(5):443-451. PMID: 28114506.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. The Call of "The Wild"-Type GIST: It's Time for Domestication. J Natl Compr Canc Netw. 2017 05; 15(5):551-554. PMID: 28476734.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    25. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med. 2016 12 14; 14(1):339. PMID: 27974047.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    26. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 10; 14(10):1286-1312. PMID: 27697982.
      View in: PubMed   Mentions: 174     Fields:    Translation:Humans
    27. A systematic review of clinically available gene expression profiling assays for stage II colorectal cancer: initial steps toward genetic staging. Am J Surg. 2016 Oct; 212(4):700-714. PMID: 27637150.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    28. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016 06; 35(2):263-75. PMID: 26857926.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    29. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. PMID: 27185373.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    30. Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA. J Gastrointest Surg. 2016 06; 20(6):1132-40. PMID: 27025710.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    31. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 01; 7(9):9707-17. PMID: 26848768.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    32. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. . 2016 04; 15(4):743-52. PMID: 26873727.
      View in: PubMed   Mentions:
    33. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015 Dec; 26(12):2505. PMID: 26489442.
      View in: PubMed   Mentions: 3     Fields:    
    34. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    35. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015 09; 26(9):1923-1929. PMID: 26091808.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    36. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer. PLoS One. 2015; 10(6):e0126898. PMID: 26083491.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    37. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. . 2015; 14(13):2121-8. PMID: 25950492.
      View in: PubMed   Mentions:
    38. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. . 2015 Jun; 14(6):1488-94. PMID: 25852059.
      View in: PubMed   Mentions:
    39. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015 Feb 20; 6(5):3033-42. PMID: 25596748.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    40. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):194-227. PMID: 25691612.
      View in: PubMed   Mentions: 113     Fields:    Translation:Humans
    41. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. . 2015; 14(8):1252-9. PMID: 25695927.
      View in: PubMed   Mentions:
    42. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. . 2015; 14(11):1730-7. PMID: 25928476.
      View in: PubMed   Mentions:
    43. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015 Jan; 13(1):78-108. PMID: 25583772.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    44. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8. PMID: 24942463.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    45. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. PMID: 24797821.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    46. In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844. J Clin Oncol. 2015 Mar 10; 33(8):e41-4. PMID: 24638008.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    47. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst. 2013 Dec 04; 105(23):1814-20. PMID: 24231453.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    48. Leptomeningeal Metastasis from Appendiceal Adenocarcinoma: Case Report and Literature Review. J Gastrointest Cancer. 2012 Sep; 43 Suppl 1:108-10. Mahta A, Kim RY, Fanta PT, Lawson JD, Kesari S. PMID: 21826409.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):406-14. PMID: 22687195.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    50. Schistosomiasis and signet ring cell carcinoma of the rectum. Ann Diagn Pathol. 2012 Oct; 16(5):385-7. PMID: 21546296.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    51. Gastric cancer. Curr Probl Cancer. 2011 May-Jun; 35(3):97-127. Lawson JD, Sicklick JK, Fanta PT. PMID: 21635986.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    52. Hairy cell leukemia. Cancer Treat Res. 2008; 142:193-209. Fanta PT, Saven A. PMID: 18283787.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    53. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2001; 47(1):83-8. Taylor CW, Dorr RT, Fanta P, Hersh EM, Salmon SE. PMID: 11221967.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    54. Diagnostic frozen prostate sextant biopsies: an approach for preserving protein and RNA for additional studies. Prostate. 2000 Sep 01; 44(4):296-302. Scott KM, Fanta P, Calaluce R, Dalkin B, Weinstein RS, Nagle RB. PMID: 10951494.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    55. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers. Gynecol Oncol. 1998 Nov; 71(2):308-12. Monk BJ, Alberts DS, Burger RA, Fanta PT, Hallum AV, Hatch KD, Salmon SE. PMID: 9826477.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    56. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol. 1997; 39(6):493-7. Alberts DS, Fanta PT, Running KL, Adair LP, Garcia DJ, Liu-Stevens R, Salmon SE. PMID: 9118460.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    57. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome. Gynecol Oncol. 1994 Dec; 55(3 Pt 2):S156-63. Federico M, Alberts DS, Garcia DJ, Emerson J, Fanta P, Liu R, Salmon SE. PMID: 7835801.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    58. Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst. 1992 Apr 01; 84(7):489-94. Taylor CW, Lui R, Fanta P, Salmon SE. PMID: 1545438.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans